These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 34201607)
1. Analysis of the Role of FRMD5 in the Biology of Papillary Thyroid Carcinoma. Gaweł AM; Ratajczak M; Gajda E; Grzanka M; Paziewska A; Cieślicka M; Kulecka M; Oczko-Wojciechowska M; Godlewska M Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34201607 [TBL] [Abstract][Full Text] [Related]
3. Upregulation of TRIB2 by Wnt/β-catenin activation in BRAF Wang N; Wen J; Ren W; Wu Y; Deng C Cancer Chemother Pharmacol; 2021 Jul; 88(1):155-164. PubMed ID: 33860836 [TBL] [Abstract][Full Text] [Related]
4. MicroRNA-150-5p affects cell proliferation, apoptosis, and EMT by regulation of the BRAF Yan R; Yang T; Zhai H; Zhou Z; Gao L; Li Y J Cell Biochem; 2018 Nov; 119(11):8763-8772. PubMed ID: 30126001 [TBL] [Abstract][Full Text] [Related]
5. BRAF Wen SS; Wu YJ; Wang JY; Ni ZX; Dong S; Xie XJ; Wang YT; Wang Y; Huang NS; Ji QH; Ma B; Qu N Thyroid; 2024 Oct; 34(10):1246-1259. PubMed ID: 39162997 [No Abstract] [Full Text] [Related]
6. Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model. Duquette M; Sadow PM; Husain A; Sims JN; Antonello ZA; Fischer AH; Song C; Castellanos-Rizaldos E; Makrigiorgos GM; Kurebayashi J; Nose V; Van Hummelen P; Bronson RT; Vinco M; Giordano TJ; Dias-Santagata D; Pandolfi PP; Nucera C Oncotarget; 2015 Dec; 6(40):42445-67. PubMed ID: 26636651 [TBL] [Abstract][Full Text] [Related]
7. BRAF-activated WT1 contributes to cancer growth and regulates autophagy and apoptosis in papillary thyroid carcinoma. Chen X; Lin S; Lin Y; Wu S; Zhuo M; Zhang A; Zheng J; You Z J Transl Med; 2022 Feb; 20(1):79. PubMed ID: 35123502 [TBL] [Abstract][Full Text] [Related]
8. Low-Density Lipoprotein Receptor Is a Key Driver of Aggressiveness in Thyroid Tumor Cells. Revilla G; Ruiz-Auladell L; Vallverdú NF; Santamaría P; Moral A; Pérez JI; Li C; Fuste V; Lerma E; Corcoy R; Pitoia F; Escolà-Gil JC; Mato E Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446330 [TBL] [Abstract][Full Text] [Related]
9. Epigenetically upregulated WIPF1 plays a major role in BRAF V600E-promoted papillary thyroid cancer aggressiveness. Zhang T; Shen X; Liu R; Zhu G; Bishop J; Xing M Oncotarget; 2017 Jan; 8(1):900-914. PubMed ID: 27863429 [TBL] [Abstract][Full Text] [Related]
11. Hypermethylation of the RSK4 promoter associated with BRAF V600E promotes papillary thyroid carcinoma. Yin Y; Che K; Hu J; Hua H; Dong A; Wang J; Yu J; Zhang Q; Zhao S; Zhao Y; Wang P; Wang F; Wang Y; Chi J; Sun W Int J Oncol; 2020 May; 56(5):1284-1293. PubMed ID: 32319586 [TBL] [Abstract][Full Text] [Related]
12. Key candidate genes associated with BRAF Yu X; Zhong P; Han Y; Huang Q; Wang J; Jia C; Lv Z J Cell Physiol; 2019 Dec; 234(12):23369-23378. PubMed ID: 31161615 [TBL] [Abstract][Full Text] [Related]
13. BRAF and KRAS mutations in papillary thyroid carcinoma in the United Arab Emirates. Al-Salam S; Sharma C; Afandi B; Al Dahmani K; Al-Zahrani AS; Al Shamsi A; Al Kaabi J PLoS One; 2020; 15(4):e0231341. PubMed ID: 32315324 [TBL] [Abstract][Full Text] [Related]
14. Associations of the BRAF V600E Mutation and PAQR3 Protein Expression with Papillary Thyroid Carcinoma Clinicopathological Features. Gao J; Ma XP; Deng FS; Jiang L; Jia WD; Li M Pathol Oncol Res; 2020 Jul; 26(3):1833-1841. PubMed ID: 31758408 [TBL] [Abstract][Full Text] [Related]
15. BRAF Shi C; Cao J; Shi T; Liang M; Ding C; Lv Y; Zhang W; Li C; Gao W; Wu G; Man J World J Surg Oncol; 2020 Jun; 18(1):145. PubMed ID: 32593310 [TBL] [Abstract][Full Text] [Related]
16. Identification of a Recurrent LMO7-BRAF Fusion in Papillary Thyroid Carcinoma. He H; Li W; Yan P; Bundschuh R; Killian JA; Labanowska J; Brock P; Shen R; Heerema NA; de la Chapelle A Thyroid; 2018 Jun; 28(6):748-754. PubMed ID: 29768105 [TBL] [Abstract][Full Text] [Related]
17. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model. Danysh BP; Rieger EY; Sinha DK; Evers CV; Cote GJ; Cabanillas ME; Hofmann MC Oncotarget; 2016 May; 7(21):30907-23. PubMed ID: 27127178 [TBL] [Abstract][Full Text] [Related]
19. BRAF V600E Gene Mutation Is Associated With Bilateral Malignancy of Papillary Thyroid Cancer. Liu Z; Lv T; Xie C; Di Z Am J Med Sci; 2018 Aug; 356(2):130-134. PubMed ID: 30219154 [TBL] [Abstract][Full Text] [Related]
20. Association between diffuse lymphocytic infiltration and papillary thyroid cancer aggressiveness according to the presence of thyroid peroxidase antibody and BRAF Lee YK; Park KH; Park SH; Kim KJ; Shin DY; Nam KH; Chung WY; Lee EJ Head Neck; 2018 Oct; 40(10):2271-2279. PubMed ID: 29935011 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]